GlassScriptPhysician profile
John B Ingram
NPI 1134319619
$129,807.35
in general payments reported to CMS, 2019-2025
19 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $12K · 2021: $13K · 2022: $17K · 2023: $23K · 2024: $35K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Consulting Fee: $6,435 · Travel and Lodging: $5,448 · Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,235.00 |
| Consulting Fee | $6,435.00 |
| Travel and Lodging | $5,447.99 |
| Food and Beverage | $1,684.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $95,433.52 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Eisai INC. | $33,023.70 | 2019-2022 | |
| Livanova USA, INC. | $443.05 | 2019-2020 | |
| Sk Life Science, INC. | $323.43 | 2024-2025 | Xcopri |
| Greenwich Biosciences, INC. | $215.04 | 2019-2020 | |
| Ptc Therapeutics, INC. | $58.75 | 2019-2022 | |
| Pyros Pharmaceuticals, INC. | $54.04 | 2024 | Vigpoder |
| Piramal Critical Care | $45.83 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $24.27 | 2019 | |
| Orchard Therapeutics North America | $23.24 | 2025 | Lenmeldy |
| Jazz Pharmaceuticals INC. | $21.69 | 2022 | |
| Acadia Pharmaceuticals INC | $20.45 | 2023 | Daybue |
| Astrazeneca Pharmaceuticals LP | $19.80 | 2025 | Wainua |
| Supernus Pharmaceuticals, INC. | $18.97 | 2020 | |
| Saol Therapeutics INC. | $18.69 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $17.25 | 2019 | |
| Genzyme Corporation | $16.21 | 2022 | |
| Medtronic, INC. | $15.43 | 2025 | Linq II |
| Catalyst Pharmaceuticals, INC. | $13.99 | 2023 | Fycompa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.